Progress with a new gene therapy in severe skin disease

A serious skin disease that causes large painful blisters may finally be close to a medical solution. A new gene therapy developed by Stanford Medicine, administered on the skin as a gel, has shown remarkably positive phase III results for the treatment of wounds that have remained unhealed for several years. An FDA approval could come as early as Q1 2023.

Read the article at biostock.se:

https://www.biostock.se/en/2022/12/progress-with-a-new-gene-therapy-in-severe-skin-disease/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/